Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

CytoDyn Shares Outstanding 2010-2025 | CYDY

CytoDyn shares outstanding from 2010 to 2025. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  
CytoDyn Annual Shares Outstanding
(Millions of Shares)
2024 970
2023 837
2022 677
2021 588
2020 421
2019 272
2018 175
2017 138
2016 95
2015 58
2014 47
2013 30
2012 25
2011 21
2010 19
2009 14
CytoDyn Quarterly Shares Outstanding
(Millions of Shares)
2025-02-28 1,228
2024-11-30 1,221
2024-08-31 1,198
2024-05-31 970
2024-02-29 982
2023-11-30 959
2023-08-31 924
2023-05-31 837
2023-02-28 832
2022-11-30 813
2022-08-31 788
2022-05-31 677
2022-02-28 696
2021-11-30 663
2021-08-31 633
2021-05-31 588
2021-02-28 578
2020-11-30 578
2020-08-31 556
2020-05-31 421
2020-02-29 432
2019-11-30 389
2019-08-31 365
2019-05-31 272
2019-02-28 296
2018-11-30 259
2018-08-31 219
2018-05-31 175
2018-02-28 178
2017-11-30 158
2017-08-31 152
2017-05-31 138
2017-02-28 142
2016-11-30 136
2016-08-31 124
2016-05-31 95
2016-02-29 105
2015-11-30 84
2015-08-31 72
2015-05-31 58
2015-02-28 59
2014-11-30 56
2014-08-31 56
2014-05-31 47
2014-02-28 55
2013-11-30 45
2013-08-31 31
2013-05-31 30
2013-02-28 30
2012-11-30 30
2012-08-31 29
2012-05-31 25
2012-02-29 25
2011-11-30 22
2011-08-31 22
2011-05-31 21
2011-02-28 22
2010-11-30 21
2010-08-31 20
2010-05-31 19
2010-02-28 19
2009-11-30 20
2009-08-31 18
2009-05-31 14
2009-02-28 15
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.485B $0.000B
CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has completed Phase 2 clinical trials with demonstrated antiviral activity in humans and is currently in Phase 3 development. PRO 140 blocks the HIV co-receptor CCR5 on T cells, which prevents viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from seven Phase 1 and Phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several months of interruption from conventional drug therapy.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $85.830B 32.20
Zoetis (ZTS) United States $72.858B 27.18
Daiichi Sankyo, - (DSNKY) Japan $48.987B 24.92
Takeda Pharmaceutical (TAK) Japan $45.406B 9.03
Sandoz Group AG (SDZNY) Switzerland $21.173B 0.00
Summit Therapeutics (SMMT) United States $18.114B 0.00
Merck (MKKGY) Germany $17.092B 12.52
United Therapeutics (UTHR) United States $13.964B 12.35
Shionogi (SGIOY) Japan $13.347B 13.37
Neurocrine Biosciences (NBIX) United States $12.169B 41.68
IPSEN (IPSEY) France $9.836B 0.00
Orion OYJ (ORINY) Finland $8.979B 24.28
Corcept Therapeutics (CORT) United States $8.083B 65.71
Stevanato Group S.p.A (STVN) Italy $7.365B 45.04
Madrigal Pharmaceuticals (MDGL) United States $6.500B 0.00
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.153B 0.00
Grifols, S.A (GRFS) Spain $5.528B 0.00
Ionis Pharmaceuticals (IONS) United States $5.486B 0.00
Ono Pharmaceutical (OPHLF) Japan $4.777B 14.53
Soleno Therapeutics (SLNO) United States $3.782B 0.00
Catalyst Pharmaceuticals (CPRX) United States $3.010B 10.55
Crinetics Pharmaceuticals (CRNX) United States $2.937B 0.00
Hypermarcas (HYPMY) Brazil $2.857B 18.79
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.326B 12.58
BioCryst Pharmaceuticals (BCRX) United States $2.162B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $2.125B 0.00
Recursion Pharmaceuticals (RXRX) United States $1.850B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $1.764B 0.00
Guardian Pharmacy Services (GRDN) United States $1.677B 0.00
Indivior (INDV) United States $1.577B 6.69
Evotec AG (EVO) Germany $1.445B 0.00
ARS Pharmaceuticals (SPRY) United States $1.407B 0.00
Dyne Therapeutics (DYN) United States $1.403B 0.00
Ocular Therapeutix (OCUL) United States $1.211B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.121B 22.43
Harrow (HROW) United States $1.030B 0.00
Ardelyx (ARDX) United States $1.000B 0.00
Collegium Pharmaceutical (COLL) United States $0.963B 5.19
Avadel Pharmaceuticals (AVDL) Ireland $0.906B 0.00
Enliven Therapeutics (ELVN) United States $0.853B 0.00
Cronos Group (CRON) Canada $0.806B 0.00
Xeris Biopharma Holdings (XERS) United States $0.794B 0.00
Akebia Therapeutics (AKBA) United States $0.767B 0.00
AleAnna (ANNA) United States $0.669B 0.00
KalVista Pharmaceuticals (KALV) United States $0.609B 0.00
Xencor (XNCR) United States $0.579B 0.00
Bioventus (BVS) United States $0.574B 14.56
USANA Health Sciences (USNA) United States $0.559B 12.16
Regulus Therapeutics (RGLS) United States $0.550B 0.00
Elite Pharmaceuticals (ELTP) United States $0.545B 0.00
Savara (SVRA) United States $0.542B 0.00
Relay Therapeutics (RLAY) United States $0.523B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.492B 0.00
Altimmune (ALT) United States $0.474B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.473B 0.00
Zevra Therapeutics (ZVRA) United States $0.471B 0.00
Siga Technologies (SIGA) United States $0.443B 9.25
Tourmaline Bio (TRML) United States $0.416B 0.00
Organogenesis (ORGO) United States $0.414B 0.00
Verve Therapeutics (VERV) United States $0.411B 0.00
Oruka Therapeutics (ORKA) United States $0.398B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.360B 9.72
Heron Therapeutics (HRTX) United States $0.293B 0.00
Nature's Sunshine Products (NATR) United States $0.269B 24.85
Aquestive Therapeutics (AQST) United States $0.237B 0.00
ProKidney (PROK) United States $0.232B 0.00
MediWound (MDWD) Israel $0.226B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.219B 0.00
Wellgistics Health (WGRX) United States $0.191B 0.00
OmniAb (OABI) United States $0.188B 0.00
Nanobiotix S.A (NBTX) France $0.181B 0.00
Esperion Therapeutics (ESPR) United States $0.180B 0.00
4D Molecular Therapeutics (FDMT) United States $0.178B 0.00
Avita Medical (RCEL) United States $0.177B 0.00
Liminatus Pharma (LIMN) $0.164B 0.00
Procaps Group, S.A (PROCF) Luxembourg $0.164B 0.00
Journey Medical (DERM) United States $0.159B 0.00
Korro Bio (KRRO) United States $0.152B 0.00
Profound Medical (PROF) Canada $0.151B 0.00
Inhibikase Therapeutics (IKT) United States $0.148B 0.00
Aclaris Therapeutics (ACRS) United States $0.146B 0.00
Aldeyra Therapeutics (ALDX) United States $0.141B 0.00
Protara Therapeutics (TARA) United States $0.134B 0.00
Larimar Therapeutics (LRMR) United States $0.132B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.130B 0.00
Nektar Therapeutics (NKTR) United States $0.128B 0.00
Lyell Immunopharma (LYEL) United States $0.125B 0.00
Innate Pharma SA (IPHYF) France $0.122B 0.00
Lexeo Therapeutics (LXEO) United States $0.117B 0.00
VAXART, INC (VXRT) United States $0.116B 0.00
Achieve Life Sciences (ACHV) Canada $0.113B 0.00
Cassava Sciences (SAVA) United States $0.108B 0.00
Ironwood Pharmaceuticals (IRWD) United States $0.106B 0.00
Fractyl Health (GUTS) United States $0.103B 0.00
OptiNose (OPTN) United States $0.097B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.093B 0.00
Cardiol Therapeutics (CRDL) Canada $0.093B 0.00
Champions Oncology (CSBR) United States $0.086B 14.09
Galectin Therapeutics (GALT) United States $0.082B 0.00
Arch Biopartners (ACHFF) Canada $0.079B 0.00
Dominari Holdings (DOMH) United States $0.077B 0.00
Inotiv (NOTV) United States $0.076B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.075B 55.89
Pyxis Oncology (PYXS) United States $0.075B 0.00
ESSA Pharma (EPIX) Canada $0.073B 0.00
Surrozen (SRZN) United States $0.073B 0.00
Unicycive Therapeutics (UNCY) United States $0.072B 0.00
Telomir Pharmaceuticals (TELO) United States $0.068B 0.00
Vivani Medical (VANI) United States $0.068B 0.00
Assertio Holdings (ASRT) United States $0.066B 0.00
Metagenomi (MGX) United States $0.064B 0.00
Nutriband (NTRB) United States $0.062B 0.00
Context Therapeutics (CNTX) United States $0.061B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.059B 0.00
Allergy Therapeutics (AGYTF) United Kingdom $0.059B 0.00
Gain Therapeutics (GANX) United States $0.056B 0.00
Prelude Therapeutics (PRLD) United States $0.055B 0.00
Century Therapeutics (IPSC) United States $0.052B 0.00
Mural Oncology (MURA) Ireland $0.051B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.049B 0.00
PMV Pharmaceuticals (PMVP) United States $0.048B 0.00
NRx Pharmaceuticals (NRXP) United States $0.048B 0.00
Karyopharm Therapeutics (KPTI) United States $0.045B 0.00
Avalo Therapeutics (AVTX) United States $0.044B 0.00
ElectroCore (ECOR) United States $0.039B 0.00
Acrivon Therapeutics (ACRV) United States $0.039B 0.00
Iterum Therapeutics (ITRM) Ireland $0.038B 0.00
FibroGen (FGEN) United States $0.035B 0.00
Rafael Holdings (RFL) United States $0.034B 0.00
SCYNEXIS (SCYX) United States $0.031B 0.00
PolyPid (PYPD) Israel $0.030B 0.00
Tempest Therapeutics (TPST) United States $0.025B 0.00
Enlivex Therapeutics (ENLV) Israel $0.023B 0.00
CASI Pharmaceuticals (CASI) China $0.023B 0.00
Natural Alternatives (NAII) United States $0.020B 0.00
Relmada Therapeutics (RLMD) United States $0.020B 0.00
Lipocine (LPCN) United States $0.019B 0.00
BioVie (BIVI) United States $0.019B 0.00
DURECT (DRRX) United States $0.019B 0.00
Jupiter Neurosciences (JUNS) United States $0.019B 0.00
VYNE Therapeutics (VYNE) United States $0.017B 0.00
TherapeuticsMD (TXMD) United States $0.017B 0.00
Mannatech (MTEX) United States $0.017B 0.00
GlycoMimetics (GLYC) United States $0.017B 0.00
Ernexa Therapeutics (ERNA) United States $0.015B 0.00
MEI Pharma (MEIP) United States $0.014B 0.00
ProPhase Labs (PRPH) United States $0.014B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.013B 0.00
Cosmos Health (COSM) United States $0.013B 0.00
Vivos Therapeutics (VVOS) United States $0.013B 0.00
BioLineRx (BLRX) Israel $0.012B 0.00
Scienture Holdings (SCNX) United States $0.012B 0.00
Talphera (TLPH) United States $0.011B 0.00
Minerva Neurosciences (NERV) United States $0.010B 1.68
Kiora Pharmaceuticals (KPRX) United States $0.009B 0.00
Biomerica (BMRA) United States $0.009B 0.00
Addex Therapeutics (ADXN) Switzerland $0.009B 0.00
Phio Pharmaceuticals (PHIO) United States $0.009B 0.00
Mangoceuticals (MGRX) United States $0.008B 0.00
Ainos (AIMD) United States $0.008B 0.00
Carisma Therapeutics (CARM) United States $0.008B 0.00
Citius Pharmaceuticals (CTXR) United States $0.007B 0.00
Nuvilex (PMCB) United States $0.007B 0.00
Klotho Neurosciences (KLTO) United States $0.007B 0.00
Traws Pharma (TRAW) United States $0.007B 0.00
Lyra Therapeutics (LYRA) United States $0.006B 0.00
Indaptus Therapeutics (INDP) United States $0.006B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.006B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.006B 0.00
TransCode Therapeutics (RNAZ) United States $0.006B 0.00
Plus Therapeutics (PSTV) United States $0.005B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.005B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.005B 0.00
Aptorum Group (APM) United Kingdom $0.005B 0.00
Xenetic Biosciences (XBIO) United States $0.005B 0.00
Clearmind Medicine (CMND) Canada $0.004B 0.00
Conduit Pharmaceuticals (CDT) United States $0.004B 0.00
Alaunos Therapeutics (TCRT) United States $0.004B 0.00
Incannex Healthcare (IXHL) Australia $0.004B 0.00
Jaguar Animal Health (JAGX) United States $0.004B 0.00
PainReform (PRFX) Israel $0.004B 0.00
XORTX Therapeutics (XRTX) Canada $0.004B 0.00
InMed Pharmaceuticals (INM) Canada $0.004B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.003B 0.00
SciSparc (SPRC) Israel $0.003B 0.00
Redhill Biopharma (RDHL) Israel $0.003B 0.00
CERo Therapeutics Holdings (CERO) United States $0.003B 0.00
Heatwurx (PCSA) United States $0.003B 0.00
Qualigen Therapeutics (QLGN) United States $0.003B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
TNF Pharmaceuticals (TNFA) United States $0.002B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
SHINECO (SISI) China $0.001B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.001B 0.00
China SXT Pharmaceuticals (SXTC) China $0.001B 0.00
Petros Pharmaceuticals (PTPI) United States $0.000B 0.00
Universe Pharmaceuticals INC (UPC) China $0.000B 0.00
Aditxt (ADTX) United States $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Silence Therapeutics (SLN) United Kingdom $0.000B 0.00